Biomarkers of joint tissue metabolism in canine osteoarthritic and arthritic joint disorders  by Hegemann, N. et al.
Osteoarthritis and Cartilage (2002) 10, 714–721
© 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved. 1063–4584/02/$35.00/0




SocietyBiomarkers of joint tissue metabolism in canine osteoarthritic and
arthritic joint disorders
N. Hegemann*, B. Kohn†, L. Brunnberg† and M. F. Schmidt*
*Institute of Immunology and Molecular Biology, Faculty of Veterinary Medicine, Free University of Berlin,
Germany
†Clinic for Small Animals, Faculty of Veterinary Medicine, Free University of Berlin, Germany
Summary
Objective: To explore the levels of matrix metalloprotease-3 (MMP-3), tissue inhibitor of metalloproteases-1 (TIMP-1), 5D4 keratan sulfate,
and two 3B3 chondroitin-sulfate epitopes in several canine osteoarthritic and inflammatory arthropathies.
Methods: Blood and synovial fluid were obtained from 103 dogs with rupture of the anterior cruciate ligament (ACLR), osteochondritis
dissecans (OCD), fragmented coronoid process (FPC), patella luxation (PL), hip dysplasia (HD) or infectious arthritis. Dogs with
non-musculosceletal disorders were used as controls. The biomarkers were measured by immunoassays.
Results: Median levels of synovial MMP-3, TIMP-1 and molar ratios of MMP/TIMP-1 were significantly higher in the arthritis than in the
control group. The release of 5D4 keratan sulfate epitope and serum 3B3 neoepitope was reduced in arthritis patients. Increases in synovial
TIMP-1 in OA were less pronounced and the molar ratio of MMP-3/TIMP-1 remained far below 1.0, demonstrating a surplus of the protease
inhibitor. In osteoarthritic patients median levels of synovial 5D4 keratan sulfate were up-regulated after ACLR and PL and were inversely
correlated with increasing duration of lameness. Serum TIMP-1 levels were significantly reduced in the joint disorder group when compared
with the control group.
Conclusion: Our observations present the TIMP-1 serum level as a potential marker for the detection of degenerative changes in cartilage
and also indicate that in canine OA, the MMP-3 mediated matrix destruction is not of major importance. However MMP-3 seems to be a
sensitive marker for the local inflammation in canine arthritis. © 2002 OsteoArthritis Research Society International. Published by Elsevier
Science Ltd. All rights reserved.
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Osteoarthritis (OA) is a slow progressive disorder of
synovial joints that affects about 20% of the canine popu-
lation over 1 year of age. This joint disorder is characterized
by a loss of balance between synthesis and degeneration
of the articular cartilage constituents leading to subsequent
erosion of joint cartilage, remodeling of the underlying
bone, osteophyte formation and variable degrees of
synovitis1.
The most common causes of secondary OA seen in
small animal practice are anterior cruciate ligament rupture
(ACLR), osteochondritis dissecans (OCD), fragmented
coronoid process (FPC) and hip dysplasia (HD). The
majority of ACLRs are a result of chronic degeneration of
the ligaments themselves caused by repeated stresses or
by immune mediated synovitis. Experimental transection of
the ACL (ACLT) in dogs results in similar pathological
changes in the cartilage and serves as a model for the
studies of OA. OCD is an enchondral ossification abnor-
mality leading to formation of cartilage flaps in the shoulder,714elbow, stifle or tarsal joint. FPC is caused by asynchronous
growth of radius and ulna and HD is characterized by joint
laxity of the coxofemoral joint2,3.
Early diagnosis of OA is a major problem both in
veterinary and human medicine because the diagnosis is
routinely established on the basis of the clinical and radio-
graphic changes that occur only in the later stages of
disease. Therefore biochemical markers of joint disease
are of considerable interest as an expedient to distinguish
pre-clinical diseases, to predict prognosis and to monitor
the response to drug and surgical therapy.
This approach employs measurement of serum or
synovial fluid levels of articular cartilage macromolecules,
such as proteoglycans or glycosaminoglycans, and matrix-
degrading enzymes.
The 5D4 keratan sulfate epitope has been widely used in
studies of dogs with ACLR4,5 or the corresponding exper-
imental OA model6–9. Some other proposed markers of
altered cartilage metabolism in OA are the two 3B3
epitopes on the chondroitin sulfate chains10,11. Levels of
these markers were shown to be elevated in osteoarthritic
knee joints of dogs12,13.
The increased breakdown of the extracellular cartilage
matrix is considered to be catalysed by the matrix metallo-
proteases (MMPs) and the aggrecanases, members of
the ADAM-TS (a desintegrin and metalloproteinase with
thrombospondin motivs) family14. The activities of MMPs
are strictly regulated by endogenous tissue inhibitors of
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SAMPLESJoint disorder group
Dogs referred to the Clinic for Small Animals of the Free
University of Berlin for treatment of ACLR, OCD, FPC, PL,
HD or arthritis were studied. The arthritis group includes
dogs with acute infectious (poly-) arthritis of the knees,
carpi and tarsi caused by different bacteria or viruses. The
diagnosis was based on clinical and radiological examin-
ation. Patient age, sex, and body weight and duration of
clinical signs after ACLR were recorded (Table I). During
surgery, synovial fluid from the affected knee and serum
were collected.Control group
Serum of dogs (N=26) presented at the clinic for non-
musculosceletal diseases were used as control samples.
Lack of gross signs of OA was confirmed by visual inspec-
tion. Synovial fluid samples (N=4) were obtained from
mature dogs that were euthanatized for non-orthopaedic
reasons. In these dogs lack of signs of OA were confirmed
by radiological examination of the synovial joints.Sample processing
Serum and synovial fluid samples were centrifuged by
6500 × g for 10 minutes. Supernatants were stored at
−80°C until assayed. The minimum sample volume for all
determinations was 500 l synovial fluid and 1.5 ml serum.TIMP-1 ASSAY
The ELISA based on previously described protocols for
human TIMP25,26. ELISA plates were coated with 50 ng/
well of an antidog TIMP-1 monoclonal antibody. Serum
samples were diluted 1:10 and synovial fluid 1:100.
Standards of recombinant canine TIMP-1 were prepared in
a concentration range of 27.5–0.2 ng/ml and a rabbit anti-
human TIMP-1 polyclonal antibody (Biotrend) was used at
dilution of 1:1200. Incubation with a peroxidase conjugated
goat antirabbit IgG (1:4000, Sigma) was followed and TMB
(3,3′, 5,5′-tetramethyl-benzidine) was added as peroxidase
substrate.STROMELYSIN-1 (MMP-3) ASSAY
An ELISA similar to the one described by Lark et al.22
and Walakovits et al.27 was used. A mouse antidog-
stromelysin-1 monoclonal antibody served as a trapping
agent in a concentration of 100 ng/ml. Synovial samples
were diluted 1:8 in saline. The second antibody, an antidog
stromelysin-1 polyclonal antibody was added in a dilution of
1:6000. Recombinant canine stromelysin was used as
standard in a concentration range of 63.0–0.49 ng/ml.5D4 KERATAN SULFATE ASSAY
This ELISA was performed as described earlier28.Table I
















Patient age Median 6 5 1 1 7 4 4
Range <1–13 1–14 <1–6 <1–2 2–12 1–9 <1–10
Bodyweight (kg) Median 22 34 41 34 30 38 34
Range 7–70 8–73 22–60 25–62 10–62 30–55 30–40
Sex Male 20 22 9 7 6 5 4
Female 10 32 5 3 3 4 3
*Synovial fluid available for only four dogs (30 in total).3B3 CHONDROITIN SULFATE ASSAYS
The 3B3 epitopes were measured with an ELISA as
described29,30 with following variation. CS standards were
prepared from digested aggrecan (aggrecan monomer
from bovine articular cartilage, Sigma) in the concentration
range of 250–0.98 ng/ml. The fluids were considered to
have a concentration of less than 10 ng/ml if the levels of
chondroitin-sulfate were below the detection limit of the
assay even at 1:5 dilutions.metalloproteases (TIMPs), which form inhibitory complexes
with MMPs in a 1:1 stochiometry15. Several studies have
suggested that there may be a relative deficit of TIMPs in
comparison to MMPs in the osteoarthritic joint16–18. MMP-3
or stromelysin-1 is capable of degrading proteoglycan,
laminin, fibronectin, or non-helical collagen, and is essen-
tial for the activation of other proMMPs19. Elevated levels of
MMP-3 and TIMP-1 were demonstrated in cartilage and
synovial fluid of human patients having OA or rheumatoid
arthritis (RA)20,21, as well as in studies of experimental
canine OA22–24.
The aim of this study was to explore the potential of a
combination of biochemical markers for early diagnosis of
canine OA. For the first time MMP-3, TIMP-1, 5D4 keratan
sulfate epitope, 3B3 (−) and (+) chondroitin-sulfate epitope
levels were measured together in the body fluids of dogs
with spontaneous ACLR, FPC, OCD, HD, PL, infectious
arthritis and in a control population by different ELISA
systems. This approach allows to define reference ranges
and to investigate the possible relationships between dif-
ferent biochemical markers and the duration of lameness
following ACLR and the various diseases.
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Quantitation was achieved by reference to a standard
curve, using the cubic-spline method (BioTek Instruments).
The concentrations of the marker substances in the
samples were determined by using the absorbance values
falling at the 40–50% inhibition of the standard curve. The
ELISA data were analysed using the statistical program
SPSS 10.0.
The Mann–Whitney U-test was used for comparison of
different biomarkers. Spearman’s rank correlation coef-
ficient was used to compare the serum and synovial fluid
values and also the biomarkers and the duration of clinical
signs of ACLR. P-values less than 0.05 were considered
significant.Fig. 1. Synovial concentrations of the biomarkers. Comparison of the values obtained in control dogs (N=4), dogs with osteoarthritic disorders
[ACLR (N=54), FPC (N=14), OCD (N=10), HD (N=9) and PL (N=9)] and dogs with arthritis (N=7). Boxes represent the interquartile range,
i.e. the middle 50% of the data, between the 25th and 75th quartile. Whiskers represent the largest and smallest observed scores that are less
than 1.5 box lengths from the end of the box. (a) 5D4 keratan sulfate and 3B3(+) chondroitin-sulfate epitopes. (b) 3B3(−) chondroitin-sulfate
epitope, MMP-3 and TIMP-1. *Statistically significant difference (P<0.05) relative to the median of the control animals.Results
The concentrations of 5D4 keratan sulfate, 3B3(−) and
3B3(+) chondroitin-sulfate, MMP-3 and TIMP-1 in the
synovial fluid and serum of control dogs and dogs suffering
from different osteoarthritic or inflammatory arthropathies
were measured. Figure 1 shows the comparison of the
synovial biomarker concentrations and Fig. 2 those of the
serum concentrations. The OA group is divided by primary
aetiology. Statistically significant differences of the con-
centrations were calculated vs the corresponding control
values.
In the analysed samples a moderate correlation became
apparent between age and the synovial biomarkers
5D4 (r=0.519), and MMP-3 (r=0.388). There were no
Osteoarthritis and Cartilage Vol. 10, No. 9 717differences in the levels of the biomarkers between females
and males. The TIMP-1, 5D4 and 3B3(−) levels in serum
were not significantly correlated with those in the synovial
fluid. In contrast MMP-3 (r=0.567, P<0.05) and 3B3(+)
(r= −0,594, P<0.05) serum levels correlated with the
corresponding synovial fluid levels.Fig. 2. Serum concentrations of the biomarkers. Comparison of the values obtained in control dogs (N=20), dogs with osteoarthritic disorders
[ACLR (N=54), FPC (N=14), OCD (N=10), HD (N=9) and PL (N=9)] and dogs with arthritis (N=7). Boxes represent the interquartile range,
i.e. the middle 50% of the data, between the 25th and 75th quartile. Whiskers represent the largest and smallest observed scores that are
less than 1.5 box lengths from the end of the box. (a) 3B3 (−) and 3B3 (+) chondroitin sulfate epitopes, MMP-3 and TIMP-1. (b) Enlarged
view of (a) (in the range 0 to 200 ng/ml). 3B3 (−) chondroitin-sulfate epitope and MMP-3. (c) 5D4 keratan sulfate. *Statistically significant
difference (P<0.05) relative to the median of the control animals.ACLR-GROUP (N=54)
Synovial 5D4 and TIMP-1 were markedly increased in
ACLR compared with the control patients. In contrast,
serum TIMP-1 values were down-regulated (P<0.05). The
highest 5D4 synovial fluid values (max. 1800 g/ml) were
observed in the first weeks after injury of the ACL, thendropping to levels of about 100 g/ml. Synovial fluid 5D4
(r= −836, P<0.05), 3B3(+) (r= −536, P<0.05), MMP-3
(r= −288, P<0.05), TIMP-1 (r= −254, P<0.05) are inversely
correlated with the duration of clinical signs (Fig. 3).
However the composition of the synovial fluid altered
after ACLR, reflected by a statistically significant decline of
the 5D4/3B3(+) ratio (−0.253, P<0.05) and increase of the
3B3(−)/3B3(+) ratio (r=0.355, P<0.05).
A strong correlation between the synovial MMP-3 and
TIMP-1 values was not obvious (r=0.183, P<0.05). How-
ever, active MMP-3 is inhibited by stoichometric amounts of
TIMP-1. Assuming that canine MMP-3 has a molecular
weight approximately 2.3 fold of canine TIMP-1 (Mr:
56 kDa; M : 23 kDa), a line showing where TIMP isr
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demonstrated that in molar terms all patients with ACLR
had levels of TIMP-1 exceeding those of MMP-3. The molar
ratio of MMP-3/TIMP-1 remained under concentrations of
1.0 during the first 48 weeks after injury of the cruciate
ligament, too.FPC-GROUP (N=14)
Concentrations of synovial biomarkers did not differ
markedly from the control values but dogs with FPC had
significant higher serum 5D4 and 10 fold lower serum
TIMP-1 levels than the control animals (P<0.05).OCD-GROUP (N=10)
The release of serum TIMP-1 was reduced about 37
times in the OCD vs the control group (P<0.05).PATELLA LUXATION-GROUP (N=9)
Serum of dogs with patella luxation contained about 40
times less TIMP-1 than the corresponding control samples.
Serum 3B3(+) was reduced too. In contrast, synovial 5D4
and TIMP-1 were up-regulated (P<0.05).HIP DYSPLASIA-GROUP (N=9)
Synovial TIMP-1 levels were markedly increased
(P<0.05), but in contrast the corresponding serum
levels were down-regulated, demonstrating the missing
correlation of these values.ARTHRITIS-GROUP (N=7)
We also analysed serum and synovial fluid of seven
dogs with diverse infectious joint disorders. Synovial fluid
contained about 27 times more MMP-3 than the control
samples. Increases in TIMP-1 were less pronounced. The
molar ratios of MMP-3/TIMP-1 were also significantly
up-regulated over 1.0 (P<0.05), indicating a surplus of the
catabolic enzyme. Increases in serum MMP-3 were less
pronounced, but the serum levels correlated with the cor-
responding synovial fluid levels (r=0.567, P<0.05). TIMP-1
serum levels were markedly down regulated. The release
of the synovial 5D4 keratan sulfate epitope and serum 3B3
neoepitope was significantly reduced in these arthritis
patients, too.
In summary, the median serum TIMP concentration was
significantly reduced in the entire joint disorder group
compared with the reference group of dogs affected by
non-orthopaedic disorders (P<0.001). Concentrations of
synovial MMP-3 were low both in the control and in the
entire OA group. The arthritis group showed significantly
increased concentrations of synovial MMP-3 compared to
the OA (P<0.005) or to the control group (P<0.05).Fig. 3. Inverse correlation between the duration of clinical signs
after ACLR and the synovial fluid 5D4 keratan sulfate levels. Each
point represents one sample (N=32). The correlation was calcu-
lated using the Spearman’s rank correlation coefficient (r= −0.836
and P=0.005).Fig. 4. Molar MMP-3/TIMP-1 ratio below 1.0 in the synovial fluid of
dogs with osteoarthritic and inflammatory disorders. This figure
shows the synovial MMP-3 levels vs the synovial TIMP-1 levels.
The line represents the concentration where the enzyme and its
inhibitor exist in equimolar proportions.Discussion
Cartilage destruction is a major characteristic of OA and
is promoted by multiple matrix degrading enzymes, includ-
ing the MMPs and aggrecanases. MMP-3 has been impli-
cated as one key enzyme in the pathogenesis of OA,
because it is able to damage proteoglycans and collagen
and is crucial for activation of other MMPs.
This is the first study to characterize the stromelysin-1
(MMP-3) and TIMP-1 levels in dogs with naturally occurring
OA and infectious arthritis. We could not detect any
increase at all in synovial MMP-3 in dogs with various
osteoarthritic joint disorders, whereas synovial TIMP-1
levels were increased in these dogs, demonstrating a molar
excess of TIMP-1 over MMP-3 in the synovial fluid.
Recently similar observations had been made in naturally
occurring equine OA31.
Therefore, our data supports the hypothesis that the
matrix degeneration in osteoarthritic joints could be pro-
moted by other proteases like the recently identified
aggrecanase-1 and -214. Alternatively, the mild synovitis
seen in canine OA may increase the clearance of the
proteins from the canine joint and decrease the synovial
fluid concentrations of the determined substances32.
Our observations vary from those obtained in a study of
human OA induced by ACLR in which an elevation of
synovial MMP-3 and a molar excess of MMP-3 over
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trast, canine cartilage was shown to become hypertrophic
for the first two years after injury of the ACL33. Thus, assays
of the above markers in dogs during the first two years after
injury will not detect any loss of cartilage (e.g., imbalance of
MMPs over inhibitors) as found in human OA.
At present there are only few other studies on canine
MMP-3 or TIMP-1. In dogs with OA induced by tibial valgus
osteotomy a moderate rise of synovial MMP-3 and TIMP-1
was found, but the molar ratio was not altered dramati-
cally23. The mild histological changes caused by this bone
deformation differ from those caused by destabilization of
the joint with ACLR34. MMP-3 activity is increased sig-
nificantly in cartilage of ACL deficient joints24. During
immobilization of the canine knee joint a decrease of
synovial TIMP-1 was recorded whereas values for MMP-3
remained at the level of the control samples35,36.
The most striking results of our study were the high
MMP-3 and TIMP-1 concentrations in synovial fluid of dogs
with infectious arthritis. Inflammatory synovial fluid con-
tained about 27 times more MMP-3 than non-inflammatory
synovial fluid. The molar ratios between MMP-3/TIMP-1
have raised over 1.0, confirming the hypothesis that
MMP-3 is a sensitive marker for the local inflammation in
this disease. This is in accordance with previous reports of
high levels of MMP-3 in the synovial fluid and serum
samples from human RA patients37–39. Inflammatory
stimuli like IL-1 and TNF- were shown to stimulate the
expression of MMP-3 in canine synovium and cartilage22.
The serum TIMP-1 levels found in our control samples
were surprisingly high, showing up to a 40-fold increase
compared to the arthropathies samples [see Fig. 2(a)]. This
presents the TIMP-1 serum level as a potential marker for
degenerative changes in cartilage. A recent study that
examined the TIMP-1 serum level of human patients with
HD found a strong correlation with progression of joint
narrowing40. Presently it is not clear whether unrelated
diseases, which have not been diagnosed in our group of
patients, cause also high TIMP-1 concentrations. This
possibility cannot be excluded because the control samples
were obtained from dogs submitted to the hospital for
non-musculosceletal diseases. In this context it is note-
worthy that in a recent study Su et al.15 found that
TIMP-1 mRNAs were inducible by different serum factors. A
possible explanation for the wide range of all biomarker
values demonstrated in this study could be the time lapse
before initial examination (0.1–48 weeks), the presence of
severe synovitis in some of the examined dogs and the
different extent in joint damage (data not shown).
Furthermore, no correlation between the synovial and
serum TIMP-1, 5D4 and 3B3 (−) values could be demon-
strated, which is in line with data from previous reports on
canine keratan sulfate and chondroitin-sulfate4,13. The
synovial inflammation present in osteoarthritic joints could
affect the clearance rate of the measured markers from the
joint and cause the different concentrations in correspond-
ing blood and synovial fluid samples. Enhanced clearance
from the canine joint has been reported for some proteins,
e.g. albumin41.
It should be also emphasized that we found a significant
decline of the synovial 5D4 keratan sulfate and the 5D4
keratan sulfate/3B3(+) chondroitin sulfate ratio with
increasing duration of clinical signs after ACLR which is in
contrast with the increase of the 3B3(−)/3B3(+)
chondroitin-sulfate ratio and may reflect changes in the
metabolism and composition of proteoglycans. Previous
reports have shown that during the development of canineOA newly synthesized proteoglycans lead to an increase in
the ratios of chondroitin-sulfate to keratan sulfate and
of chondroitin-4-sulfate to chondroitin-6-sulfate. This is
believed to reflect the synthesis of proteoglycans charac-
teristic of immature cartilage during OA42,43. Our results
are in agreement with those observed in dogs after rupture
of the ACL6 and in the canine meniscectomy model13.
In conclusion, our results demonstrate that there is no
significant rise of synovial MMP-3 in joints affected by
naturally occurring OA, whereas inflammatory synovial fluid
contains about 27 times more MMP-3 than non-
inflammatory synovial fluid and serum levels will directly
reflect the conditions occurring in the joint. Taken together,
our data demonstrate that MMP-3 is more an indicator of
the inflammatory process than of the matrix degeneration.
Assays of synovial fluid samples will more accurately
reflect a derailed extracellular matrix metabolism in
arthropathies, but MMP-3 and TIMP-1 serum concen-
trations could be of some value in detecting changes in
metabolism of the canine cartilage as well.Acknowledgments
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